Rosuvastatin versus Protease Inhibitor Switching for Hypercholesterolaemia in HIV-infected Adults.

This study compares two approaches for lowering high cholesterol in HIV-positive adults who are on certain antiretroviral medications. High cholesterol is a common side effect of some HIV drugs. The study compares adding a cholesterol-lowering drug (rosuvastatin) versus switching the HIV drug that is causing the problem, to see which approach works better over 12 weeks. You may be eligible if: - You are 18 or older and HIV-positive - You have been on stable HIV treatment including a ritonavir-boosted protease inhibitor for at least 6 months - Your HIV is well controlled (undetectable viral load for at least 3 months) - Your total cholesterol is above 5.5 mmol/L - You have a meaningful cardiovascular risk (Framingham score 8% or above, or diabetes, or family history of early heart disease) You may NOT be eligible if: - You have taken a statin medication in the last 12 weeks - You have previously had muscle damage from a statin - You have an existing diagnosis of heart disease or stroke - You are pregnant or may become pregnant - You have significant liver or kidney problems Talk to your doctor about whether this trial might be right for you.